Expression analysis of genes involved in epigenetic regulation and apoptosis in human malignant haematopoietic cell lines treated with 5-azacytidine

Journal of B.U.ON.

Volumn 16, Issue 1, 2011, Pages 116-122

  Stankov, Karmen ^a   Bogdanovic, G ^b   Kojic, V ^b   Stankov, S ^c   Jojic, N ^a   Popovic, L ^b   Popovic, S ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b ONCOLOGY INSTITUTE OF VOJVODINA   (Serbia)

^c University Novi Sad   (Serbia)

Author keywords

5 Azacytidine; Demethylation; Myelodysplastic syndrome

Indexed keywords

AZACITIDINE; COMPLEMENTARY DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P15; SUPEROXIDE DISMUTASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MYELODYSPLASTIC SYNDROME; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; MYELODYSPLASTIC SYNDROMES; OXIDATIVE STRESS; RNA, MESSENGER;

EID: 79954473227     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 287-294.
2. Buckstein R, Yee K, Wells RA. 5-Azacytidine in myelodysplastic syndromes: A clinical practice guideline. Cancer Treat Rev 2010, doi: 10.1016/j.ctrv.2010. 05.006
3. Papaggeli PC, Kortsaris AC, Matsouka PT. Aberrant methylation of c-myc and c-fos protooncogenes and p53 tumor suppressor gene in myelodysplastic syndromes and acute non-lymphocytic leukemia. J BUON 2003; 8: 341-350. (Pubitemid 38660086)
4. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2"-deoxycytidine in human cancer cell lines. Blood 2009; 113: 659-667.
5. Flotho C, Claus R, Batz C et al. The DNA methyltransferase inhibitors azacytidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23: 1019-1028.
6. Loaiza-Bonilla A, Gore SD, Carraway HE. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. Curr Opin Hematol. 2010; 17: 104-109.
7. Stankov K, Stankov S, Popovic S. Translational research in complex etiopathogenesis and therapy of hematological malignancies: the specific role of tyrosine kinases signaling and inhibition. Med Oncol 2009: 26: 437-444.
8. Musolino C, Sant'antonio E, Penna G et al. Epigenetic therapy in myelodysplastic syndromes. Eur J Haematol 2010; 84: 463-473.
9. Cui M, Wen Z, Chen J, Yang Z, Zhang H. 5-Aza-2′-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1. Med Oncol 2010; 27: 278-285.
10. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010; 24: 317-330.
11. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008; 20: 705-710.
12. Franco R, Schoneveld O, Georgakilas A, Panayiotidis A. Oxidative stress, DNA methylation and carcinogenesis. Cancer Letters 2008; 266: 6-11
13. Chen J, Odenike O, Rowley J. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010; 10: 23-36
14. Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol 2010; 14: 505-510.
15. Balada E, Ordi-Ros J, Serrano-Acedo S, Martinez-Lostao L, Rosa-Leyva M, Vilardell-Tarrés M. Transcript levels of DNA methyltransferases DNMT1, DNMT3A and DNMT3B in CD4+ T cells from patients with systemic lupus erythematosus. Immunology 2008; 124: 339-347.
16. Länger F, Dingemann J, Kreipe H, Lehmann U. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leukemia Res 2005; 29: 325-329. (Pubitemid 40127060)
17. Cor A. The relationship between DNA methylation and expression of three different DNA methyltransferases in ovarian cancer. Radiol Oncol 2000; 34: 369-374. (Pubitemid 32049488)
18. Ecke I, Petty F, Rosenberger A et al. Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res 2009; 69: 887-895.
19. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J. The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leukemia Res 2010; 34: 899-905.
20. Bogdanovic G, Jurisic V, Kraguljac N et al. Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome. Leukemia Res 2007; 31: 1097-1105.
21. Bogdanovic G, Jakimov D, Stojiljkovic B, Jurisic V. The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS. Med Oncol 2007; 24: 419-424. (Pubitemid 350135935)
22. Grudeva-Popova J. New options in the treatment of myelodysplastic syndrome. J BUON 2005; 10: 35-42. (Pubitemid 41319764)
23. Greenberg P. Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 2010; 150: 131-143.
24. Khan R, Schmidt-Mende J, Karimic M et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Experim Hematol 2008; 36: 149-157.
25. Xiong H, Qiu H, Zhuang L, Xiong H, Jiang R, Chen Y. Effects of 5-Aza-CdR on the proliferation of human breast cancer cell line MCF-7 and on the expression of Apaf-1 gene. J Huazhong Univ Sci Technolog Med Sci 2009; 29: 498-502.
26. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 2010; 38: 4313-4324.
27. Frosina G. Prophylaxis of oxidative DNA damage by formamidopyrimidine-DNA glycosylase. Int J Cancer 2006; 119: 1-7.
28. Klungland A, Bjelland S. Oxidative damage to purines in DNA: role of mammalian Ogg1. DNA Repair 2007; 6: 481-488. (Pubitemid 46371389)
29. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123: 8-13. (Pubitemid 351705186)
30. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398-6406.
31. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lübbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leukemia Res 2007; 31: 497-506.
32. Gao S, Mobley A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leukemia Res 2008; 32: 771-780. (Pubitemid 351323931)
33. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resistance Updates 2004; 7: 97-110. (Pubitemid 38736063)
34. Madesh M, Zong WX, Hawkins BJ et al. Execution of superoxide-induced cell death by the proapoptotic Bcl-2-related proteins Bid and Bak. Mol Cell Biol 2009; 29: 3099-3112.